Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study)
Authors' conclusion
Our data suggest that people with type 2 diabetes may have even higher health gain when getting vaccinated as compared with non-diabetic persons, eliminating the marked, COVID-19-related excess risk of this population. Boosters could restore protection.
Study context
- Population
- Total Hungarian population during the Delta wave; persons with T2D and non-diabetic controls free from chronic diseases
- Participants
- 672,240 vs 2,974,102
- Exposure
- Vaccinated vs unvaccinated persons with T2D and non-diabetic controls
- T2Dn = 672,240
- Controlsn = 2,974,102reference
- Outcome
- Vaccine effectiveness and persistence of different COVID vaccines (adjusted IRR)
Methodological detailsnational registry data, mixed-effect negative binomial regression
- National registry data
- Mixed-effect negative binomial regression
Main finding
As reported in the abstract
Adjusted VE of primary Pfizer-BioNTech against infection, aged 65-100 years · 14-120 days postvaccination
Observational data: associations, not effects.
Further findings
| Outcome | T2D | Controls | Times higher mortality rate (95% CI) |
|---|---|---|---|
| COVID-19-related mortality, unvaccinated elderly persons with T2D vs 'healthy' controlsUnvaccinated elderly | 2.68 (2.47–2.91) | ||
| Booster VE against infection, Pfizer-on-Pfizer, aged 65-100 years | 89.1% (CI 88.1–89.9) | 86.9% (CI 85.8–88.0) | |
| Booster VE against infection, Pfizer-on-Sinopharm, aged 65-100 years | 88.3% (CI 87.2–89.2) | 87.8% (CI 86.8–88.7) |
COVID-19-related mortality, unvaccinated elderly persons with T2D vs 'healthy' controls
- Primary immunization equalized the risk of COVID-19 mortality between the two groups
VE against mortality after booster
- VE declined over time; booster restored effectiveness against mortality to over 90%
Original publication
Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study). BMJ Open Diabetes Res Care. Published 24 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →